Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative, non-squamous, non-small cell lung cancer.

Trial Details

NCT ID

NCT05098132

Phase

PHASE1 / PHASE2

Sponsor

Synthekine

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

STK-012
pembrolizumab
pemetrexed
carboplatin

Locations (sample)

Tucson, Arizona, United States|32.22174,-110.92648
Beverly Hills, California, United States|34.07362,-118.40036
Fullerton, California, United States|33.87029,-117.92534
La Jolla, California, United States|32.84727,-117.2742
Newport Beach, California, United States|33.61891,-117.92895

Key Eligibility Criteria

Phase 1 \[closed to enrollment\]
Phase 2 \[open to enrollment\]:
Diagnosis of non-small cell lung cancer (NSCLC).
Stage IV or Stage IIIB/IIIC and not a candidate for definitive treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →